Literature DB >> 15186570

Rheumatology and musculoskeletal medicine.

Graham Davenport1.   

Abstract

Musculoskeletal disease accounts for a large proportion of a general practitioner's (GP's) workload. Proper management can not only improve quality of care, but also increase job satisfaction and reap rewards under the new contract. Osteoporosis creates a huge socioeconomic burden of disease and disability. Identifying high-risk groups in primary care and using preventative treatment can result in a substantial reduction in morbidity and mortality. GPs can help by presenting a unified lifestyle message, advising on fall prevention, and providing effective treatment; in particular, calcium and vitamin D for female nursing home residents. Osteoarthritis is eminently treatable in primary care with a number of management options for GPs, in addition to drug therapy. Glucosamine and chondroitin have few side effects and are worth recommending to patients with mild knee osteoarthritis. Rheumatoid arthritis can cause significant disability, which can be limited by early diagnosis, referral, and treatment. Severe refractory rheumatoid arthritis may warrant referral for consideration of biologic therapy. Assessment of the cardiovascular risk and possible use of statins in rheumatoid patients may reduce their cardiovascular mortality. GPs should aim to help patients to achieve optimum quality of life by using a holistic approach and by allowing maximum choice and control over their disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15186570      PMCID: PMC1266208     

Source DB:  PubMed          Journal:  Br J Gen Pract        ISSN: 0960-1643            Impact factor:   5.386


  86 in total

1.  Determining factors of mortality in the elderly with hip fractures.

Authors:  Y Koike; H Imaizumi; E Takahashi; Y Matsubara; H Komatsu
Journal:  Tohoku J Exp Med       Date:  1999-06       Impact factor: 1.848

Review 2.  Clinical consequences of vertebral fractures.

Authors:  P D Ross
Journal:  Am J Med       Date:  1997-08-18       Impact factor: 4.965

3.  Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

Authors:  R Maini; E W St Clair; F Breedveld; D Furst; J Kalden; M Weisman; J Smolen; P Emery; G Harriman; M Feldmann; P Lipsky
Journal:  Lancet       Date:  1999-12-04       Impact factor: 79.321

4.  Significant increases in serum and plasma concentrations of matrix metalloproteinases 3 and 9 in patients with rapidly destructive osteoarthritis of the hip.

Authors:  Kensaku Masuhara; Tsuyoshi Nakai; Katsuyuki Yamaguchi; Satoshi Yamasaki; Yasuyuki Sasaguri
Journal:  Arthritis Rheum       Date:  2002-10

5.  Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs.

Authors:  L A García-Rodríguez; C Huerta-Alvarez
Journal:  Epidemiology       Date:  2001-01       Impact factor: 4.822

6.  Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

Authors:  F E Silverstein; G Faich; J L Goldstein; L S Simon; T Pincus; A Whelton; R Makuch; G Eisen; N M Agrawal; W F Stenson; A M Burr; W W Zhao; J D Kent; J B Lefkowith; K M Verburg; G S Geis
Journal:  JAMA       Date:  2000-09-13       Impact factor: 56.272

7.  Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study.

Authors:  M C Chapuy; R Pamphile; E Paris; C Kempf; M Schlichting; S Arnaud; P Garnero; P J Meunier
Journal:  Osteoporos Int       Date:  2002-03       Impact factor: 4.507

8.  Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study.

Authors:  Karel Pavelká; Jindriska Gatterová; Marta Olejarová; Stanislav Machacek; Giampaolo Giacovelli; Lucio C Rovati
Journal:  Arch Intern Med       Date:  2002-10-14

9.  Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial.

Authors:  J Y Reginster; R Deroisy; L C Rovati; R L Lee; E Lejeune; O Bruyere; G Giacovelli; Y Henrotin; J E Dacre; C Gossett
Journal:  Lancet       Date:  2001-01-27       Impact factor: 79.321

10.  Topical diclofenac versus placebo: a double blind, randomized clinical trial in patients with osteoarthritis of the knee.

Authors:  D Grace; J Rogers; K Skeith; K Anderson
Journal:  J Rheumatol       Date:  1999-12       Impact factor: 4.666

View more
  2 in total

1.  An inverse association between self-reported arthritis and mortality in the elderly: findings from the national long-term care survey.

Authors:  Alexander M Kulminski; Irina V Kulminskaya; Svetlana V Ukraintseva; Kenneth Land; Anatoli I Yashin
Journal:  Rejuvenation Res       Date:  2008-02       Impact factor: 4.663

Review 2.  Statin treatment for rheumatoid arthritis: a promising novel indication.

Authors:  Kosmas I Paraskevas
Journal:  Clin Rheumatol       Date:  2007-12-08       Impact factor: 2.980

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.